𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of lymphosarcoma in the dog with L-asparaginase

✍ Scribed by Lloyd J. Old; Edward A. Boyse; H. A. Campbell; Robert S. Brodey; J. Fidler; Joseph D. Teller


Publisher
John Wiley and Sons
Year
1967
Tongue
English
Weight
449 KB
Volume
20
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


An isocratic fluorescence HPLC assay for
✍ Christa E. Nath; Luciano Dallapozza; Adam E. Eslick; Ashish Misra; Deborah Carr; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB 👁 1 views

## Abstract A novel assay for the determination of l‐asparaginase activity in human plasma is described that is based on the HPLC quantitation of l‐aspartic acid produced during enzyme incubation. Methods for monitoring l‐asparagine depletion are also described. Chromatography of l‐aspartic acid, l

L-asparaginase used with cytosine arabin
✍ Smithson, William A. ;Gilchrist, Gerald S. ;Burgert, E. Omer 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 458 KB

## Abstract Eleven patients with acute lymphocytic leukemia in relapse were treated with L‐asparaginase and cytosine arabinoside (1‐β‐D‐arabinofuranosylcytosine) in induction therapy and the same drugs plus cyclophosphamide in maintenance therapy. Three patients had complete remissions lasting 6, 1

Hypersensitive reactions and antibody fo
✍ D. Killander; A. Dohlwitz; L. Engstedt; S. Franzén; G. Gahrton; B. Gullbring; G. 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

One hundred and fourteen patients with acute leukemia, 57 children (10 AML and 47 ALL) and 57 adults (37 AML and 20 ALL) were treated with L-asparaginase (Asnase) 200 or 1000 IU/kg daily for 30 days unless withdrawn on account of side effects. Combinations with other cytotoxic drugs were used in all

Short courses of cytosine arabinoside an
✍ H. Ekert; J. H. Colebatch; R. N. Matthews 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB 👁 2 views

Courses of cytosine arabinoside followed by L-asparaginase were administered for 4 days each to 17 children with previously treated acute lymphatic leukemia, at 14to 27-day intervals. Complete or partial remission occurred in 81% of patients after the third or fourth course of therapy. Rlaintenance